<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702347</url>
  </required_header>
  <id_info>
    <org_study_id>C2018/35</org_study_id>
    <nct_id>NCT04702347</nct_id>
  </id_info>
  <brief_title>Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study</brief_title>
  <official_title>Genetic Testing in Upper Tract Urothelial Carcinoma (UTUC): the Epicheck Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Puigvert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Puigvert</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Upper tract urothelial carcinoma (UTUC) is a rare tumor associated with bladder cancer in up&#xD;
      to 50% of cases. Its incidence is rising due to improved detection and bladder cancer&#xD;
      survival. The diagnosis of UTUC is challenging because more than 35% of the standard biopsies&#xD;
      can result inconclusive. The grading of UTUC cells, which delivers the most important data&#xD;
      for the choice between a kidney-sparing surgery (KSS) and a radical treatment, is upgraded in&#xD;
      30% of radical nephroureterectomies. The follow-up of UTUC after KSS requires an invasive&#xD;
      procedure as a diagnostic ureteroscopy for a minimum of 5 years, and urinary cytology has low&#xD;
      diagnostic power.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The aim of the study is to evaluate the accuracy (overall and stratified for grade) of a DNA&#xD;
      methylation urine biomarker test (Bladder EpiCheckTM) in UTUC, and to compare it with current&#xD;
      standard (urinary cytology). The secondary objective is to show its applicability in the&#xD;
      specific clinical scenario of UTUC surveillance after kidney-sparing surgery and related&#xD;
      cost-effectiveness.&#xD;
&#xD;
      Design, Setting, and Participants:&#xD;
&#xD;
      From February 2019 to February 2021, 80 consecutive patients candidates to ureteroscopy for&#xD;
      suspicion of primary, recurrent or metachronous UTUC in one tertiary Referral Centers&#xD;
      (Fundaci√≤ Puigvert) giving written informed consent will be included in the study.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Bladder urine samples (&gt; 10 ml) will be collected for cytology and for the methylation test&#xD;
      before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the&#xD;
      upper urinary tract will be obtained via a ureteral catheter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, specificity, positive predictive value and negative predictive value of the test</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To test the accuracy of the urine biomarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison with urinary cytology</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To evaluate and compare performance of urinary cytology and urine biormarker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of biormarker performance in bladder and upper tract</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>To compare the accuracy of the test in situ (upper tract) and in the bladder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High grade/low grade tumors diagnosis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Sub-analysis on biormaker accuracy for low and high grade tumours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the urine biormaker for UTUC diagnosis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>A decision-making analysis will be performed in patients with UTUC suspicion, reporting the net benefit, the number of unnecessary ureteroscopies avoided</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Urologic Cancer</condition>
  <condition>Urologic Neoplasms</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine biomarker</intervention_name>
    <description>Bladder urine samples (&gt; 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine from upper urinary tract and bladder (at least 10 ml each)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients candidate to ureteroscopy for a radiological diagnosis or clinical suspicion&#xD;
        for upper tract urothelial cancer in the period from February 1st 2019 to February 28th&#xD;
        2021 will be included in this study after giving informed written consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suspected for primary or recurrent upper tract urothelial cancer requiring&#xD;
             ureteroscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease with patient unfit for ureteroscopy&#xD;
&#xD;
          -  Positive cystoscopy (concomitant presence of bladder cancer)&#xD;
&#xD;
          -  Macroscopic hematuria not self-limiting requiring upfront nephroureterectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Gallioli, MD</last_name>
    <phone>+34619588266</phone>
    <email>andrea.gallioli@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Breda, MD</last_name>
    <phone>+34618018179</phone>
    <email>albbred@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundacio Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gallioli, MD</last_name>
      <phone>+34619588266</phone>
      <email>andrea.gallioli@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Puigvert</investigator_affiliation>
    <investigator_full_name>Alberto Breda</investigator_full_name>
    <investigator_title>Chief of the Uro-Oncology Unit and Director of the Kidney Transplantation Division</investigator_title>
  </responsible_party>
  <keyword>Upper tract urothelial carcinoma</keyword>
  <keyword>Urinary biomarker</keyword>
  <keyword>Liquid biopsy</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

